POS AM

As filed with the Securities and Exchange Commission on November 6, 2018

Registration No. 333-208788

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1

TO

FORM S-3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

ImmunoCellular Therapeutics, Ltd.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   93-1301885

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

30721 Russell Ranch Road, Suite 140

West Lake Village, California 91362

(Address of principal executive offices)

 

 

Gary Titus

Chairman of the Board of Directors

ImmunoCellular Therapeutics, Ltd.

30721 Russell Ranch Road, Suite 140

West Lake Village, California 91362

(818) 264-2300

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

Glen Y. Sato

Cooley LLP

3175 Hanover Street

Palo Alto, California 94304

(650) 843-5000

 

 

Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.

If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 of the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.  ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and lit the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, please check the following box.  ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, please check the following box.  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
Emerging growth company       

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 


DEREGISTRATION OF SECURITIES

ImmunoCellular Therapeutics, Ltd. (the “Registrant”) is filing this Post-Effective Amendment to its Registration Statement on Form S-3 (File No. 333-208788) filed by the Registrant on December 30, 2015, to withdraw and remove from registration the unissued and unsold shares of the Registrant’s common stock, par value $0.0001 per share, the Registrant’s preferred stock, par value $0.0001 per share, debt securities and warrants, issuable by the Registrant pursuant to the Registration Statement.

In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance that remain unsold at the termination of the offering, the Registrant hereby removes from registration all of such securities of the Registrant registered but which remain unsold and unissued under the Registration Statement as of the date hereof.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized on November 6, 2018.

 

ImmunoCellular Therapeutics, Ltd.

By:   /s/ David Fractor
 

David Fractor

Acting Principal Financial Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, these Post-Effective Amendments to the Registration Statements have been signed by the following persons in the capacities and on the dates indicated.

 

Signature

  

Title

 

Date

/s/ David Fractor

David Fractor

  

Acting Principal Financial Officer

  November 6, 2018

/s/ Gary Titus

Gary Titus

  

Chairman of the Board of Directors and Director

  November 6, 2018

/s/ Rahul Singhvi

Rahul Singhvi, Sc.D.

  

Director

  November 6, 2018

/s/ John S. Yu

John S. Yu, M.D.

  

Director

  November 6, 2018